Abstract Objective To investigate the clinical characteristics and treatment defects in slow-to-recover children with Mycoplasma pneumoniae pneumonia (MPP) associated with airway mucous plug formation, and to provide a basis for prognostic judgment and therapeutic guidance. Methods A retrospective analysis was performed on the clinical data of 67 children with MPP who were admitted between May 2012 and May 2014 and showed airway mucous plug formation in fiberoptic bronchoscope examinations. Based on the results of re-examinations using imaging methods, all patients were classified into a slow-to-recover group (n=30) and a control group (n=37). Comparisons of clinical outcomes, laboratory indices, imaging findings, and treatment methods were performed between the two groups. The receiver operating characteristic (ROC) curves were drawn to analyze the indices with significant differences. Results The percentage of neutrophils, levels of C-reactive protein (CRP), lactic dehydrogenase (LDH), fibrinogen (FIB), and IgM in peripheral blood, and incidence of pleural effusion were significantly higher in the slow-to-recover group than in the control group (PPConclusions The fever duration, percentage of neutrophils, level of CRP, level of FIB, and treatment time of fiberoptic bronchoscope for the first time can predict a recovery time longer than two months in children with MPP associated with mucous plug formation.
About author:: 10.7499/j.issn.1008-8830.2015.05.015
Cite this article:
AN Shu-Hua,ZHANG Li-Jun,LI Jin-Ying. Prognostic judgment of children with Mycoplasma pneumoniae pneumonia associated with airway mucous plug formation[J]. CJCP, 2015, 17(5): 487-491.
AN Shu-Hua,ZHANG Li-Jun,LI Jin-Ying. Prognostic judgment of children with Mycoplasma pneumoniae pneumonia associated with airway mucous plug formation[J]. CJCP, 2015, 17(5): 487-491.
Zhao H, Li S, Cao L, et al. Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012[J]. Chin Med J (Engl), 2014, 127(7): 1244-1248.
[2]
Miyashita N, Obase Y, Ouchi K, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit[J]. J Med Microbiol, 2007, 56(Pt 12): 1625-1629.
Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen[J]. Clin Microbiol Rev, 2004, 17(4): 697-728.
[8]
Narita M, Tanaka H. Late increase of interleukin-18 levels in blood during Mycoplasma pneumoniae pneumonia[J]. Cytokine, 2012, 59(1): 18-19.
[9]
Arae K, Hirata M, Kurata S, et al. Mycoplasma pneumoniae induces interleukin-8 production via the epidermal growth factor receptor pathway[J]. Microbiol Immunol, 2011, 55(10): 748-750.
Daxboeck F, Eisl B, Burghuber C, et al. Fatal Mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl[J]. Wien Klin Wochenschr, 2007, 119(11-12): 379-384.
[12]
Oishi T, Narita M, Matsui K, et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia[J]. J Infect Chemother, 2011, 17(6): 803-806.
[13]
Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(9): 1055-1069.
[14]
Narita M, Tanaka H, Yamada S, et al. Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection[J]. Clin Diagn Lab Immunol, 2001, 8(5): 1028-1030.
Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America[J]. Clin Infect Dis, 2011, 53(7): e25-e76.
[17]
Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia[J]. Arch Intern Med, 1999, 159(21): 2576-2580.
Lu A, Wang L, Zhang X, et al. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid[J]. Pediatr Pulmonol, 2011, 46(11): 1093-1097.
